albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-22 and is reviewed periodically as new material appears.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
The use of a solvent gradient is very well developed in column chromatography but is less common in CCC. A solvent gradient is produced by increasing (or decreasing) the polarity of the mobile phase during the separation to achieve optimal resolution across a wider range of polarities. For example, a methanol-water mobile phase gradient may be employed using heptane as the stationary phase. This is not possible with all biphasic solvent systems, due to excessive loss of stationary phase created by disruption the equilibrium conditions within the column. Gradients may either be produced in steps, or continuously. In dual-mode, the mobile and stationary phases are reversed part way through the separation experiment. This requires changing the phase being pumped through the column as well as the direction of flow. Dual-mode operation is likely to elute the entire sample from the column but the order of elution is disrupted by switching the phase and direction of flow.
The medical historian Christoph Gradmann has reconstructed Koch's beliefs regarding the function of tuberculin: the medicine did not kill the bacteria but rather initiated a necrosis of the tubercular tissue, thus "starving" the tuberculosis pathogen. This idea was then outside customary medical theories, as it remains today. The tuberculin scandal was understood as a cautionary tale in regards to testing medicine. Emil von Behring's introduction of his diphtheria antitoxin in 1893 had been preceded by lengthy clinical testing, and the serum was only slowly introduced into practical use, accompanied by a critical discussion among qualified experts. Paul Ehrlich also proceeded with conspicuous caution in 1909 when introducing the first synthetically produced chemotherapeutic agent, Salvarsan, as a cure for an infectious disease, syphilis.
In the periodic table, nobelium is located to the right of the actinide mendelevium, to the left of the actinide lawrencium, and below the lanthanide ytterbium. Nobelium metal has not yet been prepared in bulk quantities, and bulk preparation is currently impossible. Nevertheless, a number of predictions and some preliminary experimental results have been done regarding its properties. The lanthanides and actinides, in the metallic state, can exist as either divalent (such as europium and ytterbium) or trivalent (most other lanthanides) metals. The former have fns2 configurations, whereas the latter have fn−1d1s2 configurations. In 1975, Johansson and Rosengren examined the measured and predicted values for the cohesive energies (enthalpies of crystallization) of the metallic lanthanides and actinides, both as divalent and trivalent metals. The conclusion was that the increased binding energy of the [Rn]5f136d17s2 configuration over the [Rn]5f147s2 configuration for nobelium was not enough to compensate for the energy needed to promote one 5f electron to 6d, as is true also for the very late actinides: thus einsteinium, fermium, mendelevium, and nobelium were expected to be divalent metals, although for nobelium this prediction has not yet been confirmed.
=== Research === The number of research projects and scientific publications on cannabidiol and other cannabinoids in pets surged in the late 2010s; nonetheless, as of December 2020, there were no hemp-derived, cannabinoid-rich registered veterinary medicinal products in any of the major regions (see § Legal status). In the US and other territories there are, however, numerous veterinary nutraceutical products available over the counter (OTC). The lack of clarity in the regulations governing veterinary hemp food supplements allows for products of questionable quality to flood the market, which may pose a risk to the wellbeing of pets and owners. To understand better the benefits of CBD and associated compounds for the quality of life of animals, companies specialized in CBD products for animals have been funding research projects.
== History == The Kingdom of Mysore was one of the three largest princely states in British India. Upon India's independence from Britain in 1947, Maharaja Jayachamarajendra Wadiyar signed the instrument of accession, with the Union of India on 9 August 1947. The territories of the erstwhile princely state of Mysore were then reconstituted into a state within the Union, on 26 January 1950, with its administrative integration into the Indian Union. In 1953 during the formation of Andhra, the Bellary district was transferred from Madras to Mysore.
Sources: en.wikipedia.org
Several of the CPK colors refer mnemonically to colors of the pure elements or notable compound. For example, hydrogen is a colorless gas, carbon as charcoal, graphite or coke is black, sulfur powder is yellow, chlorine is a greenish gas, bromine is a dark red liquid, iodine in ether is violet, amorphous phosphorus is red, rust is dark orange-red, etc. For some colors, such as those of oxygen and nitrogen, the inspiration is less clear. Perhaps red for oxygen is inspired by the fact that oxygen is normally required for combustion or that the oxygen-bearing chemical in blood, hemoglobin, is bright red, and the blue for nitrogen by the fact that nitrogen is the main component of Earth's atmosphere, which appears to human eyes as being colored sky blue. It is likely that the CPK colours were inspired by models in the nineteenth century. In 1865, August Wilhelm von Hofmann, in a talk at the Royal Institution in London, was using models made from croquet balls to illustrate valence, so he used the coloured balls available to him. (At the time, croquet was the most popular sport in England, so the balls were plentiful.) The essay "On the Combining Power of Atoms", in the 12th volume of Chemical News, states that "Hofmann, at a lecture given at the Royal Institution in April 1865 made use of croquet balls of different colours to represent various kinds of atoms (e.g. carbon black, hydrogen white, chlorine green, 'fiery' oxygen red, nitrogen blue)."
Moscow is situated on the banks of the Moskva River, which flows for about 500 kilometers (310 mi) through the East European Plain in Central Russia, not far from the natural border of the forest and the forest-steppe zone. A total of 49 bridges span the river and its canals within city limits. Moscow's elevation at the All-Russia Exhibition Center (VVC)—where the leading Moscow weather station is located—is 156 meters (512 ft). Teplostan Upland is the city's highest point at 255 meters (837 ft). The width of the city (excluding the MKAD) from west to east is 39.7 kilometers (24.7 mi), and the length from north to south is 51.8 kilometers (32.2 mi).
==== Radial glial cells ==== The radial glial cells are disposed in planes perpendicular to the axes of ventricles. One of their processes abuts the pia mater, while the other is deeply buried in grey matter. Radial glia are mostly present during development, playing a role in neuron migration. Müller cells of the retina and Bergmann glia cells of the cerebellar cortex represent an exception, being present still during adulthood. When in proximity to the pia mater, all three forms of astrocytes send out processes to form the pia-glial membrane.
GeneReviews profile NPR.org: Myostatin Therapies Hold Hope for Muscle Diseases by Jon Hamilton Times Colonist Big Wendy the muscular whippet myostatin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: O14793 (Human Growth/differentiation factor 8) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: O08689 (Mouse Growth/differentiation factor 8) at the PDBe-KB.
Sources: en.wikipedia.org
Professionals also testified on Agüero's unhealthy relationship with her mother, which the psychologists labeled as "not common". Other evidence was photos from her cell phone, which included images of animals treated like human babies, Agüero herself showing her belly, and images of hospitalized children.
== History == In October 1967, Techtron Pty Ltd merged with Varian Associates. Techtron is a manufacturer of Atomic Absorption Spectrometers and Spectral lamps. In 1982, Varian transferred the Cary UV-Visible product line to Australia. In 1997, Varian bought Chemagnetics, a Colorado-based manufacturer of solid-state NMR spectrometers. In 2002, Varian bought Ansys Technologies, Inc., a California-based manufacturer of In-Vitro Medical Devices. In 2004, Varian Inc bought Magnex Scientific, an Oxford-based manufacturer of high-field magnets. In 2005, Varian bought Polymer Laboratories, a speciality polymer analysis and manufacturing company. In 2006, Varian bought Ion Spec, an FTMS (Fourier Transform Mass Spectrometry) manufacturing company. In 2007, Varian, Inc. bought Analogix, Inc., a company specializing in flash chromatography. In 2008, Varian bought Oxford Diffraction, a British company specializing in X-ray diffraction equipment. On 27 July 2009, Agilent Technologies announced it would buy Varian Inc, for $1.5 Billion. On 14 October 2014, Agilent made the strategic decision to close its NMR business. Agilent entered the NMR business in 2010, with the acquisition of Varian. Several former Varian engineers have continued the business through private ventures, including the probe department spawning the company PhoenixNMR and the software being made open source.
In 2015, the world's first successful penis transplant took place in Cape Town, South Africa in a nine-hour operation performed by surgeons from Stellenbosch University and Tygerberg Hospital. The 21-year-old recipient, who had been sexually active, had lost his penis in a botched circumcision at 18.
She also describes the legislation as a "slippery slope towards death on demand". 24 November – Alex Cole-Hamilton, the leader of the Scottish Liberal Democrats says his party will vote down the Scottish Government's upcoming budget if it contains even a "penny" promoting Scottish independence. 25 November – In an attempt to reassure industry there will not be further tax rises for business, Chancellor Rachel Reeves tells the CBI conference she is "not coming back with more borrowing or more taxes". An online petition calling for another general election reaches two million signatures, the third largest since 2010; in response, Starmer says he is "not that surprised" that people who did not vote for Labour would want an election re-run. South Wales politicians, including MP Sir Chris Bryant and MS Heledd Fychan, have criticised what they describe as a lack of preparation and insufficient warnings ahead of the arrival of Storm Bert. The Welsh Government publishes the Levy and Registration bill to allow councils in Wales to raise a tax from visitor accommodation, with the £1.25 per person per night levy expected to be introduced from 2027. 27 November – The UK government announces an overhaul of gambling laws, which will restrict the amount people can bet online with each bet to £5 for those aged over 25 and £2 for those aged 18 to 24. A Parliamentary Commission for Standards investigation is launched into Birmingham Yardley MP and Home Office minister Jess Phillips after she failed to register an interest on time.
5-Hydroxyeicosanoid dehydrogenase (5-HEDH) or more formally, nicotinamide adenine dinucleotide phosphate (NADP+)-dependent dehydrogenase, is an enzyme that metabolizes between two eicosanoid metabolites of arachidonate 5-lipoxygenase (5-LOX): 5-hydroxyeicosatetraenoic acid (5-(S)-HETE), and its 5-keto analog 5-oxo-eicosatetraenoic acid (5-oxo-ETE). It also acts in the reverse direction, metabolizing 5-oxo-ETE to 5(S)-HETE. Since 5-oxo-ETE is 30–100-fold more potent than 5(S)-HETE in stimulating various cell types, 5-HEDH is regarded as a regulator and promoter of the influence that 5-LOX and its metabolites have on cell function. Although 5-HEDH has been evaluated in a wide range of intact cells and in crude microsome preparations, it has not yet been evaluated for its structure or gene, and most studies on it have been limited to human tissues.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.